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WS4.1 Clinical supervision improves treatment ﬁdelity to an
adherence intervention
A.L. Quittner1, A.N. Alpern1, K.A. McLean1, K.K. Marciel1, J. Zhang2,
K.A. Riekert3. 1University of Miami, Department of Psychology, Coral Gables,
FL, United States; 2Novartis Pharmaceuticals Corporation, East Hanover, United
States; 3Johns Hopkins University, Baltimore, United States
Objectives: Treatment ﬁdelity, deﬁned as implementation of interventions as
intended, positively affects efﬁcacy. To improve ﬁdelity to behavioral interventions,
providers require supervision and feedback. In iCARE (I Change Adherence and
Raise Expectations), we examined the effects of supervision on ﬁdelity over time.
Methods: iCARE is a multisite, randomized trial, which includes Problem-Solving
(PS). Behavioral Interventionists (BIs) from multidisciplinary teams conduct PS
sessions with a teen and parent to identify adherence barriers and generate solutions.
Sessions are videotaped and reviewed by a supervisor who provides feedback.
Treatment ﬁdelity is rated independently on a scale of 0−35.
Results: Preliminary data on 242 sessions by 28 BIs (12 CF centers) were
analyzed. Signiﬁcant improvements in ﬁdelity were noted after each supervision
session, with the greatest magnitude of change occurring within 3 supervisions
(Baseline M = 21.02; M post Supervision 1 = 23.01; Supervision 2 = 23.61; Super-
vision 3 = 26.09). Baseline ﬁdelity predicted ﬁdelity after Supervisions #1 (r = 0.76,
p< 0.01) and #2, but not Supervision #3 (r = 0.31, ns). Repeated measures analyses
conﬁrmed that supervision leads to better treatment ﬁdelity (t =−2.25, df = 15,
p< 0.05).
Conclusions: Supervision signiﬁcantly improved BIs’ ﬁdelity to PS steps. A
minimum of 3 supervisions optimizes ﬁdelity; however, ongoing supervision is
ideal. Supervision is central to successful delivery of behavioral interventions in
clinic settings. Future analyses will examine data from a larger sample.
Funding provided by Novartis Pharmaceuticals Corporation, Genentech, Inc., &
Cystic Fibrosis Foundation.
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J. Duckers2, R. Horne1. 1University College London, UCL School of Pharmacy,
London, United Kingdom; 2University Hospital Llandough, All Wales Adult Cystic
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Background: This study examined Cystic Fibrosis (CF) patients’ beliefs about
nebuliser treatment (NT) (necessity beliefs and concerns about potential adverse
effects) and whether beliefs were related to adherence.
Methods: CF patients completed the Beliefs about Medicines Questionnaire
(BMQ), a validated measure of treatment necessity and concerns. Adherence was
assessed using the Medication Adherence Report Scale (MARS).
Results: 59 participants completed questionnaires (mean age 27; 53% male). Many
patients harboured doubts about their personal need for NT (e.g. 31% did not agree
that without NT that they would be very ill), and only 22% participants endorsed the
need to take the full amount of their NT for it to work. The most prevalent concerns
were: ’NT is an unwelcome reminder of CF’ (46%), ’NT disrupts my life’ (40%),
’NT will become less effective is used regularly’ (40%), becoming too dependent
on NT (30%), and NT is embarrassing (25%). Over half of the sample reported
forgetting to use their NT (54%) or using it only when they feel breathless (41%).
Participants were allocated to low adherence (n = 14) vs. high adherence (n = 45)
groups according to their MARS score. Low adherence was associated with doubts
about nebuliser necessity (t(57) = −2.94, p< 0.01), and to how patients’ rated their
personal need for nebuliser relative to their concerns about potential adverse effects
(necessity-concerns differential score) (t(57) = −2.107, p< 0.05).
Conclusions: Strategies to support CF patients’ adherence to NT should consider
their necessity beliefs and concerns.
WS4.3 Barriers to adherence in cystic ﬁbrosis: the perspectives of
young patients and their parents
V. Bregnballe1, O. Schiøtz1. 1Aarhus University Hospital, Dep. of Pediatrics,
Aarhus, Denmark
Objectives: The objectives of the present study was to explore barriers to treatment
adherence perceived by young CF patients and their parents and to identify what
kind of support the young patients and their parents request from the CF center.
Methods: A questionnaire survey of a cohort of young Danish patients with cystic
ﬁbrosis aged 14 to 25 years and their parents.
Conclusions: The present study showed that the majority of adolescents with CF
and their parents experienced barriers to treatment adherence. Patients and parents
agreed that the three most common barriers encountered lack of time, forgetfulness
and unwillingness to take medication in public. A signiﬁcant, positive correlation
was found between the number of barriers and the perceived treatment burden.
Additionally, we found that almost half of the adolescents and half of the parents
conveyed a desire for more information about the potential consequences of low
adherence.
WS4.4 The effect of remote monitoring and third party intervention
on adherence with inhaled therapies in patients with cystic
ﬁbrosis using the I-neb Insight Online patient management
system
K. Pollard1, R. Watson1, S.P. Conway1, C. Etherington1, S. Ollerton2,
D. Peckham1. 1Leeds Teaching Hospital Trust, Adult Cystic Fibrosis Unit,
Leeds, United Kingdom; 2Respironics Respiratory Drug Delivery (UK) Ltd,
Philips, Chichester, United Kingdom
Inhaled therapy is an important aspect of the management of patients with Cystic
Fibrosis. Adherence to multiple, often time consuming, treatments remains a
challenge to both patients and care providers.
24 CF patients took part in a 13 week handling study of the I-neb Insight Online
patient management system conducted by Philips Respironics using the I-neb patient
logging system (PLS). PLS provided remote feedback (a record of date, time,
duration, completeness of treatment, inhalation time, rest time and mesh integrity)
to the patient, patient support programme (PSP) personnel, and clinician via the
internet. Patients were contacted by PSP if results from PLS data triggered any
alerts. A service evaluation was performed to establish whether this should be
available for all patients using I-neb.
17/24 patients completed the study. Median (range) adherence to nebulised therapy
prior to the study was 67.9% (14.28% − 96.34%) and 86.37% (34.61% − 117.58%)
during remote monitoring. Results were analysed using McNamara’s test (Minitab
Version 14). Although there was a general trend towards improved adherence this
did not reach statistical signiﬁcance (P = 0.1579).
Remote monitoring and third party intervention improved adherence in 13/17 pa-
tients who completed the study. Of those who did not improve 3 patients demon-
strated greater than 91% adherence prior to starting remote monitoring. Due to the
small numbers of patients statistical signiﬁcance was not achieved, but data suggest
clinical beneﬁt. We would conclude that I-neb Insight can have signiﬁcant impact
on improving adherence in individual patients and should be available as part of
routine clinical care.
